GutRecover's platform combines multi-omics profiling, characterised strain selection, and biomarker-driven formulation to produce defined interventions — not donor-derived preparations.
Therapies built as precisely characterised communities of bacteria — selected for complementary ecological function, not sourced from donors.
Whole-genome sequencing, bile-salt-hydrolase and 7α-dehydroxylation functional assays, and safety genomics — screening out transferable resistance and toxin genes — build a complete dossier for each clonal strain before it enters a consortium.4,22 No undefined material enters a product candidate.
Strains are chosen to restore the specific functions lost in dysbiosis — secondary-bile-acid production that resists C. difficile, short-chain-fatty-acid output, and Treg-inducing immune signals — not simply for abundance.4,12,13
Production from clonal cell banks enables the same rigorous quality controls as conventional pharmaceuticals — each batch identical, characterised against the FDA's CMC expectations for live biotherapeutic products.22 The basis for both regulatory submission and clinical credibility.
A three-stage discovery platform that turns gut ecology data into reproducible medicine. Step through each stage — or watch it run.
// Platform grounded in published mechanism — bile-acid colonisation resistance, butyrate-driven Treg induction. See sources.
Pharmaceutical-grade production processes designed for the regulatory rigour of a live biotherapeutic product.
Each consortium is produced under defined, controlled fermentation conditions — no donor variability, no undefined inputs. The manufacturing process is designed from the ground up to meet the expectations of regulatory agencies for a new class of product.
Cryopreservation, encapsulation, and stability testing are integrated into the development process, not bolted on at the end. The result is a product candidate that can be evaluated with the same rigour as a conventional pharmaceutical.
GutRecover's Casablanca R&D and early-manufacturing hub — being finalised, operational October 2026 — provides the infrastructure to accelerate characterisation and scale-up while maintaining the documentation standards required for IND and CTA submissions, in line with FDA guidance on CMC for live biotherapeutic products.22
Profiling, design, and validation run as one gated workflow — each consortium characterised, each endpoint pre-specified, each result documented to the standard a regulator expects.
See the evidence →Patent applications covering the specific strain combinations and ratios that constitute GutRecover's lead and pipeline candidates, filed in key jurisdictions.
Protection for the multi-omics profiling methods, biomarker identification processes, and manufacturing protocols that constitute the core of the GutRecover discovery engine.
A curated and characterised library of clinically relevant strains — accumulated through structured isolation campaigns and maintained under strict access controls.
Peer-reviewed papers, conference posters, and presentations from the GutRecover scientific team and affiliated academic collaborators.
Two layers: the published science our approach is built on — each entry linked to PubMed or DOI — and GutRecover's own scientific output, shown at its honest status. Conference submissions are tracked separately below.
No items of this type yet.
Live tracking of GutRecover abstracts from drafting to podium — each item shows its current stage and target venue. Status updates as submissions progress.